2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
    Neuronal Signaling
  4. TRP Channel

TRP Channel

Transient receptor potential channels

TRP Channel

Related Products

PDF 2.26 MB

TRP Channel (Transient receptor potential channel) is a group of ion channels located mostly on the plasma membrane of numerous human and animal cell types. There are about 28 TRP channels that share some structural similarity to each other. These are grouped into two broad groups: Group 1 includes TRPC ("C" for canonical), TRPV ("V" for vanilloid), TRPM ("M" for melastatin), TRPN, and TRPA. In group 2, there are TRPP ("P" for polycystic) and TRPML ("ML" for mucolipin). Many of these channels mediate a variety of sensations like the sensations of pain, hotness, warmth or coldness, different kinds of tastes, pressure, and vision. TRP channels are relatively non-selectively permeable to cations, including sodium, calcium and magnesium. TRP channels are initially discovered in trp-mutant strain of the fruit fly Drosophila. Later, TRP channels are found in vertebrates where they are ubiquitously expressed in many cell types and tissues. TRP channels are important for human health as mutations in at least four TRP channels underlie disease.

TRP Channel Isoform Specific Products:

TRP Channel Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-101389
    (R)-Methanandamide
    		Agonist 99.61%
    (R)-Methanandamide (AM-356), an analog of the endocannabinoid ligand Anandamide, is a potent CB1 agonist with a Ki of 20 nM. (R)-Methanandamide also activates vanilloid (TRPV1) receptors.
    (R)-Methanandamide
  • HY-161766
    L687
    		Activator 99.49%
    L687 is a potent activator of TRPC3/C6/C7 that can induce cellular uptake of oligonucleotides.
    L687
  • HY-N7144A
    Citronellyl acetate
    		98.0%
    Citronellyl acetate, a monoterpene product of the secondary metabolism of plants, is an orally active antinociceptive agent. Citronellyl acetate modulates TRPV1, TRPM8, ASIC, glutamate receptors, PKC, and PKA-mediated nociception. Citronellyl acetate can be used for the research of acute pain.
    Citronellyl acetate
  • HY-10863S
    Anandamide-d8
    		Activator 99.90%
    Anandamide-d8 is a deuterated labeled Anandamide. Anandamide is an endocannabinoid. Anandamide modulates both neuronal and immune functions through two protein-coupled cannabinoid receptors (CB1 and CB2). Anandamide can activate numerous other receptors like PPARS, TRPV1, and GPR18/GPR55. Anandamide also has potential anti-fungal and anti-inflammatory activities. Anandamide can be used for the research of Alzheimer’s disease (AD) and ulcerative colitis.
    Anandamide-d<sub>8</sub>
  • HY-P1651B
    SOR-C13 acetate
    		Antagonist 99.11%
    SOR-C13 acetate is the acetate salt form of SOR-C13 (HY-P1651). SOR-C13 acetate is an antagonist for transient receptor potential vanilloid 6 (TRPV 6), with an IC50 of 14 nM. SOR-C13 acetate inhibits tumor growth in SKOV-3 xenograft mouse model.
    SOR-C13 acetate
  • HY-113037CS
    Farnesyl pyrophosphate-d2 triammonium
    		Agonist
    Farnesyl pyrophosphate-d2 (Farnesyl diphosphate-d2) triammonium is a deuterium labeled Farnesyl pyrophosphate triammonium (HY-113037C). Farnesyl pyrophosphate ammonium is a metabolic intermediate in the mevalonate (MVA) pathway. It is a TRP channel (TRPM2) agonist that triggers Ca2+ influx and cell death. Farnesyl pyrophosphate ammonium is a key branch substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) synthesis. Farnesyl pyrophosphate ammonium is used in research on cerebral ischemia, neurodegenerative diseases, pancreatic cancer, inflammation, and autoimmune diseases.
    Farnesyl pyrophosphate-d<sub>2</sub> triammonium
  • HY-16413
    Protokylol hydrochloride
    		Agonist 99.07%
    Protokylol hydrochloride (Caytine hydrochloride; JB-251 hydrochloride) is the hydrochloride salt form of Protokylol (HY-114630). Protokylol hydrochloride is an agonist for β2-adrenergic receptor and TRPV1. Protokylol hydrochloride exhibits activity as a bronchodilator.
    Protokylol hydrochloride
  • HY-N0808R
    Camphor (Standard)
    		Agonist
    Camphor (Standard) is the analytical standard of Camphor. This product is intended for research and analytical applications. Camphor ((±)-Camphor) is a topical anti-infective and anti-pruritic and internally as a stimulant and carminative. However, Camphor is poisonous when ingested. Antiviral, antitussive, and anticancer activities. Camphor is a TRPV3 agonist.
    Camphor (Standard)
  • HY-132813
    Evifacotrep
    		Antagonist 99.65%
    Evifacotrep, a short transient receptor potential channel 5 and 4 (TRPC5/TRPC4) antagonist (WO2020061162, compound 100), can be used for the research of neurological diseases. Evifacotrep targets to TRPC5/TRPC4 with IC50s ≤50 nM.
    Evifacotrep
  • HY-B0151S2
    Pregnenolone-d4-1
    		Activator 99.34%
    Pregnenolone-d4-1 is the deuterium labeled Pregnenolone. Pregnenolone (3β-Hydroxy-5-pregnen-20-one) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone can protect the brain from cannabis intoxication. Pregnenolone is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels.
    Pregnenolone-d<sub>4</sub>-1
  • HY-171846
    LY3526318
    		Inhibitor 99.92%
    LY3526318 is an orally active, selective TRPA1 antagonist (IC50=5-6μM). LY3526318 blocks TRPA1 channels, inhibits pain signal transduction mediated by the channel, and exerts analgesic activity. LY3526318 is mainly used in the research of chronic pain-related fields, such as diabetic peripheral neuropathy, chronic low back pain, and pain caused by osteoarthritis.
    LY3526318
  • HY-168608
    TRPM7-IN-1
    		Inhibitor 98.83%
    TRPM7-IN-1 (compound SUD), a benzoylurea derivative, is an effective TRPM7 inhibitor. TRPM7-IN-1 induces cell cycle arrest and apoptosis, decreases the migration of MCF-7 and BGC-823 cells. TRPM7-IN-1 decreases vimentin expression and increases E-cadherin expression. TRPM7-IN-1 potentially reduces the TRPM7-like current and decreases TRPM7 expression through the PI3K/Akt signaling pathway. TRPM7-IN-1 is a potential agent to suppress the metastasis of breast and gastric cancer by inhibiting TRPM7 expression and function.
    TRPM7-IN-1
  • HY-N10319
    Artepillin C
    		Agonist 98.28%
    Artepillin C is an orally active CREB/CRTC2 inhibitor and TRPA1 covalent agonist (EC50=1.8 μM). Artepillin C inhibits CREB/CRTC2-mediated gene transcription and downregulates BMAL1 expression to regulate glucose and lipid metabolism. Artepillin C can also activate TRPA1 channels to induce spicy taste signals. Artepillin C can inhibit tumor cell proliferation, induce necroptosis, improve insulin resistance and inhibit liver lipid synthesis. Artepillin C can be used in the study of metabolic syndrome, tumor prevention and treatment, and inflammation.
    Artepillin C
  • HY-132596
    Tivanisiran
    		Inhibitor
    Tivanisiran (SYL1001) is a siRNA used for the study of dry eye disease. Tivanisiran was designed to silence transient receptor potential vanilloid 1 (TRPV1) mRNA.
    Tivanisiran
  • HY-110199
    TC-I 2014
    		Antagonist 99.07%
    TC-I 2014 (compound 5) is a potent and orally active Benzimidazole-containing transient receptor potential melastatin 8 (TRPM8) antagonist, with IC50 values of 0.8 nM, 3.0 nM and 4.4 nM for canine, human and rat channels respectively. TC-I 2014 exhibits antiallodynic properties in pain models.
    TC-I 2014
  • HY-110270
    RN-9893
    		Antagonist 99.91%
    RN-9893 is a potent and selective TRPV4 receptor antagonist with IC50 values of 320, 420 and 660 nM for mouse, human and rat channels, respectively.
    RN-9893
  • HY-B0327
    Irsogladine
    		Activator 99.88%
    Irsogladine (Dicloguamine) is an orally active gastric mucosal protective agent. Irsogladine inhibits breast cancer recurrence and lung metastasis in nude mice. Irsogladine inhibits the transcriptional activities of NF-κB and AP-1, suppresses the activities of PDE and PDE4 to elevate intracellular cAMP levels, and activates TRPV1 and KATP channels. Irsogladine enhances iNOS expression, NO production, and the activation of cAMP-responsive elements. Irsogladine inhibits the development and progression of intestinal polyps in Apc-mutant mice. Irsogladine alleviates oxidative stress, increases gastric mucosal blood flow, and stimulates the production of endogenous prostaglandins. Irsogladine promotes insulin secretion in MIN6 cells. Irsogladine inhibits tumor angiogenesis, cancer cell proliferation, and the production of proinflammatory cytokines. Irsogladine exerts protective effects on astrocytes in ethanol/hydrochloric acid-induced gastric ulcers in mice. Irsogladine prevents colitis in IL-10 gene-deficient mice by reducing the production of IL-12 and IL-23. Irsogladine upregulates gap junction intercellular communication in pancreatic cancer cells via the PKA pathway. Irsogladine is applicable to research related to breast cancer, intestinal polyposis, gastric ulcer, spontaneous colitis, glioma, liver cancer, and pancreatic cancer[5][6].
    Irsogladine
  • HY-108455
    N-Palmitoyl dopamine
    		Control 98.04%
    N-Palmitoyl dopamine (PALDA) is a endogenous, long-chain, linear fatty acid dopamide, which is inactive on TRPV1. N-Palmitoyl dopamine displays 'entourage' effects on endovanilloids N-arachidonoyl-dopamine (NADA) and anandamide.
    N-Palmitoyl dopamine
  • HY-W014325
    TRPM8 agonist WS-3
    		Agonist 99.35%
    TRPM8 agonist WS-3 is an specific agonist of TRPM8 with an EC50 of 3.7 μM. TRPM8 agonist WS-3 inhibits epileptic seizures through a TRPM8 dependent mechanism. TRPM8 agonist WS-3 can be used for research on epilepsy and other conditions.
    TRPM8 agonist WS-3
  • HY-B0985A
    Phenazopyridine
    		Antagonist 99.93%
    Phenazopyridine is a competitive SARM1 inhibitor, with IC50 145 μM. Phenazopyridine is a TRPM8 antagonist. Phenazopyridine has a local anesthetic/analgesic effect. Phenazopyridine is used to relieve painful symptoms of conditions such as cystitis and urethritis. Phenazopyridine can promote neuronal differentiation and can also be used in the study of traumatic brain injury, peripheral neuropathy and neurodegenerative diseases.
    Phenazopyridine
Cat. No. Product Name / Synonyms Application Reactivity
TRP Channel Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.